The expression of CYP2W1: A prognostic marker in colon cancer

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3869-3874

  Stenstedt, Kristina ^a,b   Hallstrom, Maria ^a   Johansson, Inger ^a   Ingelman Sundberg, Magnus ^a   Ragnhammar, Peter ^a   Edler, David ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Colonic cancer; CYP2W1; Cytochrome P450; Prognostic marker

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2W1; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; COLON CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; COLONIC NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84867025142     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Oyama T, Kagawa N, Kunugita N, Kitagawa K, Ogawa M, Yamaguchi T, Suzuki R, Kinaga T, Yashima Y, Ozaki S, Isse T, Kim YD, Kim H and Kawamoto T: Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci 9: 1967-1976, 2004. (Pubitemid 38918646)
2. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD and Melvin WT: Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 57(14): 3026-3030, 1997.
3. Rieger MA, Ebner R, Bell DR, Kiessling A, Rohayem J, Schmitz M, Temme A, Rieber EP and Wegle B: Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res 64(7): 2357-2363, 2004.
4. Jiang JG, Chen CL, Card JW, Yang S, Chen JX, Fu XN, Ning YG, Xiao X, Zeldin DC and Wang DW: Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res 65(11): 4707-4715, 2005. (Pubitemid 40740807)
5. Nishida CR, Lee M and de Montellano PRO: Efficient Hypoxic Activation of the Anticancer Agent AQ4N by CYP2S1 and CYP2W1. Mol Pharmacol 78(3): 497-502, 2010.
6. Gomez A, Nekvindova J, Travica S, Lee MY, Johansson I, Edler D, Mkrtchian S and Ingelman-Sundberg M: Colorectal cancer specific cytochrome P450 2W1 (CYP2W1): intracellular localization, glycosylation, and catalytic activity. Mol Pharmacol 78(6): 1004-1011, 2010.
7. Karlgren M, Gomez A, Stark K, Svard J, Rodriguez-Antona C, Oliw E, Bernal ML, Ramon y Cajal S, Johansson I and Ingelman-Sundberg M: Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun 341(2): 451-458, 2006. (Pubitemid 43152125)
8. Gomez A, Karlgren M, Edler D, Bernal ML, Mkrtchian S and Ingelman-Sundberg M: Expression of CYP2W1 in colon tumors: regulation by gene methylation. Pharmacogenomics 8(10): 1315-1325, 2007. (Pubitemid 350162848)
9. Edler D, Stenstedt K, Ohrling K, Hallstrom M, Karlgren M, Ingelman-Sundberg M and Ragnhammar P: The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer A pilot study. Eur J Cancer 45(4): 705-712, 2009.
10. Glimelius B, Dahl O, Cedermark B, Jakobsen A, Bentzen SM, Starkhammar H, Grönberg H, Hultborn R, Albertsson M, Påhlman L, Tveit KM and The Nordic Gastrointestinal Tumour Adjuvant Therapy Group: Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 44(8): 904-912, 2005.
11. Martinez C, Garcia Martin E, Pizarro M, Garcia-Gamito FJ and Agundez JAG: Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br J Cancer 87(6): 681-686, 2002.